LEO 29102 Cream in the Treatment of Atopic Dermatitis

Inclusion Criteria: * Clinical diagnosis of atopic dermatitis defined according to Hanifin and Rajka * IGA assessment scored as mild (2) to moderate (3) atopic dermatitis * Treatment lesions located on the trunk and limbs * Treatment lesions involving 3% to 10% of the total body surface area * Patients of either gender between 18 years and 65 years of age Exclusion Criteria: * Systemic treatment with immunosuppressive drugs or corticosteroids within 6 weeks prior to randomisation * Topical treatment with immunomodulators (pimecrolimus, tacrolimus) within 2 weeks prior to randomisation * Topical treatment with corticosteroids from WHO groups II, III or IV within 1 week prior to randomisation * Use of topical or systemic antibiotics within 2 weeks prior to randomisation * PUVA or UVB therapy within 4 weeks prior to randomisation * Clinical infection (viral, fungal or bacterial) on the treatment area * Known or suspected severe renal insufficiency or severe hepatic disorders * Patients with history of an immunocompromised disease (e.g., lymphoma, HIV, Wiskott-Aldrich Syndrome) * Patients with concomitant serious disease (e.g., cancer) which might affect the AD treatment in this trial * Females who are pregnant or are breast feeding * Females intending to temporarily or permanently stop their hormonal contraceptive regime during and up to one month post study termination visit